Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODAC Backs Allos' Folotyn Despite Fickle Data, Finds Many Paths Forward

Executive Summary

Despite short response duration and a significant number of response adjudications, The Oncologic Drugs Advisory Committee presented numerous paths forward for Allos' peripheral T-cell lymphoma agent Folotyn (pralatrexate)

You may also be interested in...



Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn

Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma

Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn

Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma

Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn

Allos gains its first U.S. indication with the accelerated approval of Folotyn (pralatrexate) in peripheral T-cell lymphoma.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel